WO2007135193A3 - Forme pharmaceutique orale multimicroparticulaire a liberation prolongee comprenant des moyens anti-mesusage et resistant a l'alcool - Google Patents

Forme pharmaceutique orale multimicroparticulaire a liberation prolongee comprenant des moyens anti-mesusage et resistant a l'alcool Download PDF

Info

Publication number
WO2007135193A3
WO2007135193A3 PCT/EP2007/055069 EP2007055069W WO2007135193A3 WO 2007135193 A3 WO2007135193 A3 WO 2007135193A3 EP 2007055069 W EP2007055069 W EP 2007055069W WO 2007135193 A3 WO2007135193 A3 WO 2007135193A3
Authority
WO
WIPO (PCT)
Prior art keywords
sustained
resistant
pharmaceutical form
oral pharmaceutical
multimicroparticulate
Prior art date
Application number
PCT/EP2007/055069
Other languages
English (en)
Other versions
WO2007135193A2 (fr
Inventor
Florence Guimberteau
Frederic Dargelas
Original Assignee
Flamel Tech Sa
Florence Guimberteau
Frederic Dargelas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flamel Tech Sa, Florence Guimberteau, Frederic Dargelas filed Critical Flamel Tech Sa
Priority to EP07729498A priority Critical patent/EP2040685A2/fr
Priority to CA2651451A priority patent/CA2651451C/fr
Priority to JP2009511528A priority patent/JP5654750B2/ja
Publication of WO2007135193A2 publication Critical patent/WO2007135193A2/fr
Publication of WO2007135193A3 publication Critical patent/WO2007135193A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/745—Polymers of hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Forme pharmaceutique multimicroparticulaire à libération modifiée capable de maintenir la libération modifiée du principe actif dans une solution alcoolique et de résister aux tentatives de mésusage.
PCT/EP2007/055069 2006-05-24 2007-05-24 Forme pharmaceutique orale multimicroparticulaire a liberation prolongee comprenant des moyens anti-mesusage et resistant a l'alcool WO2007135193A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP07729498A EP2040685A2 (fr) 2006-05-24 2007-05-24 Forme pharmaceutique orale multimicroparticulaire a liberation prolongee comprenant des moyens anti-mesusage et resistant a l'alcool
CA2651451A CA2651451C (fr) 2006-05-24 2007-05-24 Forme pharmaceutique orale multimicroparticulaire a liberation prolongee
JP2009511528A JP5654750B2 (ja) 2006-05-24 2007-05-24 持続性放出マルチ微粒子状経口医薬形態

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0604685A FR2901478B1 (fr) 2006-05-24 2006-05-24 Forme pharmaceutique orale multimicroparticulaire a liberation prolongee
FR0604685 2006-05-24

Publications (2)

Publication Number Publication Date
WO2007135193A2 WO2007135193A2 (fr) 2007-11-29
WO2007135193A3 true WO2007135193A3 (fr) 2008-06-26

Family

ID=37435577

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/055069 WO2007135193A2 (fr) 2006-05-24 2007-05-24 Forme pharmaceutique orale multimicroparticulaire a liberation prolongee comprenant des moyens anti-mesusage et resistant a l'alcool

Country Status (6)

Country Link
EP (1) EP2040685A2 (fr)
JP (1) JP5654750B2 (fr)
CN (1) CN101453994A (fr)
CA (1) CA2651451C (fr)
FR (1) FR2901478B1 (fr)
WO (1) WO2007135193A2 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
EP2957281A1 (fr) 2001-09-21 2015-12-23 Egalet Ltd. Systeme de liberation a base de polymere
EP2301526B1 (fr) 2003-03-26 2016-03-23 Egalet Ltd. Système de libération contrôlée de morphine
WO2008148798A2 (fr) 2007-06-04 2008-12-11 Egalet A/S Compositions pharmaceutiques à libération contrôlée pour un effet prolongé
CA2706931C (fr) * 2007-12-06 2015-05-12 Durect Corporation Formes posologiques pharmaceutiques orales
EP2344136B1 (fr) * 2008-09-18 2016-06-15 Purdue Pharma LP Formes galeniques comprenant de la poly(e-caprolactone)
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
WO2010089132A1 (fr) 2009-02-06 2010-08-12 Egalet A/S Composition à libération immédiate résistant à une maltraitance par prise d'alcool
NZ597283A (en) 2009-06-24 2013-07-26 Egalet Ltd Controlled release formulations
JP6141583B2 (ja) * 2010-02-24 2017-06-07 シマ ラブス インク． 濫用耐性製剤
EP4011364B1 (fr) * 2011-03-23 2023-12-13 Ironshore Pharmaceuticals & Development, Inc. Procédés et compositions pour le traitement de troubles du déficit de l'attention
CN102516473B (zh) * 2011-12-14 2013-07-24 华南理工大学 细胞片智能分离用共聚纳米复合水凝胶及其制备方法与应用
US9549899B2 (en) 2012-07-06 2017-01-24 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
EP2983468A4 (fr) 2013-03-15 2016-09-07 Durect Corp Compositions ayant un agent de modification rhéologique pour réduire une variabilité de dissolution
CA2919892C (fr) 2013-08-12 2019-06-18 Pharmaceutical Manufacturing Research Services, Inc. Comprime extrude anti-abus a liberation immediate
WO2015095391A1 (fr) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Comprimé extrudé anti-abus à libération prolongée
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9707184B2 (en) 2014-07-17 2017-07-18 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
EP3209282A4 (fr) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Forme galénique anti-abus de remplissage de liquide à libération prolongée
CA2936746C (fr) * 2014-10-31 2017-06-27 Purdue Pharma Methodes et compositions destinees au traitement du trouble de deficit d'attention
WO2018000094A1 (fr) 2016-06-29 2018-01-04 CannScience Innovations Inc. Résines de cannabis décarboxylées, leurs utilisations et leurs procédés de fabrication
EP3473246A1 (fr) 2017-10-19 2019-04-24 Capsugel Belgium NV Formulations anti-abus à libération immédiate
CN111841508B (zh) * 2020-07-28 2021-08-17 南昌航空大学 一种磺基水杨酸修饰壳聚糖/二氧化硅微球及其制备方法和应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003013476A1 (fr) * 2001-08-06 2003-02-20 Euro-Celtique S.A. Compositions et procedes servant a empecher la surconsommation d'opioides
US20030068276A1 (en) * 2001-09-17 2003-04-10 Lyn Hughes Dosage forms
WO2004026262A2 (fr) * 2002-09-23 2004-04-01 Verion, Inc. Compositions pharmaceutiques n'induisant pas l'abus
WO2004037259A1 (fr) * 2002-10-25 2004-05-06 Grünenthal GmbH Forme galenique protegee contre un usage detourne
WO2004052346A1 (fr) * 2002-12-05 2004-06-24 Eurand, Inc. Compositions pharmaceutiques contenant des composants de medicament qui ne peuvent pas etre distingues
US20050031546A1 (en) * 2003-08-06 2005-02-10 Johannes Bartholomaus Abuse-proffed dosage form
FR2872044A1 (fr) * 2004-06-28 2005-12-30 Flamel Technologies Sa Formulation pharmaceutique a base d'antibiotique sous forme microcapsulaire
FR2892937A1 (fr) * 2005-11-10 2007-05-11 Flamel Technologies Sa Forme pharmaceutique orale microparticulaire anti-mesusage

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2007181C (fr) * 1989-01-06 1998-11-24 Angelo Mario Morella Compose pharmaceutique a liberation continue
JP3677156B2 (ja) * 1997-09-05 2005-07-27 武田薬品工業株式会社 医薬
JP2002003366A (ja) * 2000-06-23 2002-01-09 Freunt Ind Co Ltd 固形薬剤用水系コーティング剤組成物
US20030059397A1 (en) * 2001-09-17 2003-03-27 Lyn Hughes Dosage forms
DE60327807D1 (de) * 2002-03-26 2009-07-09 Euro Celtique Sa Gelbeschichtete zusammensetzungen mit verzögerter freisetzung
ES2592504T3 (es) * 2003-07-17 2016-11-30 Banner Life Sciences, LLC Preparaciones de liberación controlada
TWI350762B (en) * 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
CA2572352A1 (fr) * 2004-07-01 2006-01-12 Gruenenthal Gmbh Forme posologique anti-abus pour administration par voie orale contenant du (1r, 2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
AU2005295482B2 (en) * 2004-10-15 2011-03-31 Supernus Pharmaceuticals Inc. Less abusable pharmaceutical preparations

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003013476A1 (fr) * 2001-08-06 2003-02-20 Euro-Celtique S.A. Compositions et procedes servant a empecher la surconsommation d'opioides
US20030068276A1 (en) * 2001-09-17 2003-04-10 Lyn Hughes Dosage forms
WO2004026262A2 (fr) * 2002-09-23 2004-04-01 Verion, Inc. Compositions pharmaceutiques n'induisant pas l'abus
WO2004037259A1 (fr) * 2002-10-25 2004-05-06 Grünenthal GmbH Forme galenique protegee contre un usage detourne
WO2004052346A1 (fr) * 2002-12-05 2004-06-24 Eurand, Inc. Compositions pharmaceutiques contenant des composants de medicament qui ne peuvent pas etre distingues
US20050031546A1 (en) * 2003-08-06 2005-02-10 Johannes Bartholomaus Abuse-proffed dosage form
FR2872044A1 (fr) * 2004-06-28 2005-12-30 Flamel Technologies Sa Formulation pharmaceutique a base d'antibiotique sous forme microcapsulaire
FR2892937A1 (fr) * 2005-11-10 2007-05-11 Flamel Technologies Sa Forme pharmaceutique orale microparticulaire anti-mesusage

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AJAZ S. HUSSAIN: "Preventing Alcohol Induced Dose Dumping is a Desired Product Design Feature", 26 October 2005 (2005-10-26), ACPS Meeting, pages 1 - 13, XP002409100, Retrieved from the Internet <URL:http://www.fda.gov/ohrms/dockets/ac/05/slides/2005-4187S2_02_Hussain_files/frame.htm> [retrieved on 20061123] *
PURDUE PHARMA: "Medication Guide: Palladone", 24 September 2004 (2004-09-24), USA, pages 1 - 6, XP002409102, Retrieved from the Internet <URL:http://www.joinwaypharm.com/pages/products-e-3.htm> [retrieved on 20061123] *
ROBERT J. MEYER, AJAZ S. HUSSAIN: "Mitigating the Risks of Ethanol Induced Dose Dumping from Oral Sustained/Controlled Release Dosage Forms", October 2005 (2005-10-01), FDA's ACPS Meeting, pages 1 - 4, XP002409099, Retrieved from the Internet <URL:www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4187B1_01_08-Alcohol-Induced.pdf> [retrieved on 20061123] *
U.S. FOOD AND DRUG ADMINISTRATION: "Palladone (Hydromorphone Hydrochloride Extended-Release) Capsules Questions and Answers", 13 July 2005 (2005-07-13), pages 1 - 3, XP002409101, Retrieved from the Internet <URL:http://www.fda.gov/cder/drug/infopage/palladone/palladoneQA.htm> [retrieved on 20061123] *

Also Published As

Publication number Publication date
JP2009537610A (ja) 2009-10-29
JP5654750B2 (ja) 2015-01-14
CN101453994A (zh) 2009-06-10
EP2040685A2 (fr) 2009-04-01
WO2007135193A2 (fr) 2007-11-29
FR2901478A1 (fr) 2007-11-30
CA2651451C (fr) 2013-08-20
FR2901478B1 (fr) 2015-06-05
CA2651451A1 (fr) 2007-11-29

Similar Documents

Publication Publication Date Title
WO2007135193A3 (fr) Forme pharmaceutique orale multimicroparticulaire a liberation prolongee comprenant des moyens anti-mesusage et resistant a l&#39;alcool
HK1211463A1 (en) Sprayable gel-type skin/mucosa-adhesive preparation and administration system using the preparation
WO2007002597A3 (fr) Formulations a liberation modifiee d&#39;un sel de bupropion
IL183357A0 (en) Oral medicament for the modified release of at least one active principle, in multimicrocapsule form
IL186458A0 (en) Skin enrichment using coq10 as the delivery system
WO2011049706A8 (fr) Comprimés oralement transformables
ZA200807767B (en) Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
WO2007146426A3 (fr) Nanobilles pour délivrance de médicament
HK1244819A1 (zh) Foxm1肽和包含foxm1肽的藥劑
EP2045253A4 (fr) DÉRIVÉ D&#39;ACIDE alpha-AMINÉ ET PRODUIT PHARMACEUTIQUE QUI LE COMPREND EN TANT QUE MATIÈRE ACTIVE
WO2008016677A3 (fr) Préparation et utilisation des amphétamines substituées
IL191758A0 (en) Composition with sustained release of the active ingredient, process for the preparation thereof and use thereof
IL201730A (en) History 1h - Benzaimidazole – 2 – Il – Profile – Methyl – Amino – Ethyl – 5 – Aryl – Bicyclo [2.2.2] Oct – 5 – Ann – 2 – All, Pharmaceutical preparations containing them and their use in the preparation of drugs
WO2008021410A3 (fr) Diacide de pemetrexed de haute pureté et ses procédés de préparation
EP1731609A4 (fr) INHIBITEUR DE L&#39;EXPRESSION DE Rad51, MÉDICAMENT CONTENANT L&#39;INHIBITEUR COMME INGRÉDIENT ACTIF ET UTILISATION DE CELUI-CI
WO2008003050A3 (fr) Formulations de nitrate de gallium
WO2009149058A3 (fr) Formulations de niacine à libération modifiée
WO2010052466A3 (fr) Composition pharmaceutique en aérosol
SI1742927T1 (sl) Derivati butanojske kisline, postopki za pripravo le-teh, farmacevtski sestavki, ki jih vsebujejo in terapevtske uporabe le-teh
IL209371A0 (en) C-ring-substituted pregn-4-ene-21,17-carbolactone, and pharmaceutical preparations comprising the latter
EP1813288A4 (fr) Préparation thérapeutique, formule thérapeutique, et formule combinée
EP2005964A4 (fr) Médicament pour traiter l&#39;hyperphosphatémie et son procédé de préparation
WO2010033954A3 (fr) Formulations galéniques de composés organiques
WO2011058336A3 (fr) Comprimé
WO2005097192A3 (fr) Combinaison de substances actives

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780018905.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07729498

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 5832/CHENP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2651451

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2009511528

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007729498

Country of ref document: EP